Header Logo

Connection

DAVID LONARD to Bortezomib

Back to Details
This is a "connection" page, showing publications DAVID LONARD has written about Bortezomib.
DAVID LONARD
Connection Strength
0.044
Bortezomib
  1. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.